GRIN-related neurodevelopmental disorder (GRIN-NDD) is a family of rare, genetically defined neurodevelopmental disorders caused by mutations in GRIN genes and abnormal activity of the ...
Our round-up of recent biotech financings is headed by a $140 million Series D for GRIN Therapeutics, which also scored a $570 million licensing deal with Angelini Pharma. The New York-based biotech ...
A high-level overview of VictoryShares International Free Cash Flow Growth ETF (GRIN). Stay up to date on the latest price, chart, news, analysis, fundamentals, trading and investment tools.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback